A Phase I Study of Selinexor, Ixazomib, and Dexamethasone in Patients with Recurrent or Persistent Multiple Myeloma

Full Title

An Investigator-Initiated Phase I Study of Selinexor (KPT-330), Ixazomib, and Low Dose Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma

Purpose

The purpose of this study is to evaluate different doses of the investigational drug selinexor when given with ixazomib and dexamethasone in patients with multiple myeloma that has come back or stopped responding to treatment.

Tumor suppressor proteins work inside normal cells to prevent the uncontrolled cell growth that can lead to cancer. Some cancer cells thrive by getting rid of tumor suppressor proteins. Selinexor (also known as KPT-330) is an investigational drug that works by trapping tumor suppressor proteins inside cancer cells, causing them to die or stop growing.

Ixazomib and dexamethasone are already used to treat multiple myeloma that has come back. All of the medications in this study are taken orally (by mouth).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have multiple myeloma that has come back after or stopped responding to treatment that included lenalidomide or thalidomide and a proteasome inhibitor.
  • At least 2 weeks must pass between the completion of previous treatment and entry into the study.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Nikoletta Lendvai at 212-639-3368.

Protocol

15-310

Phase

I

Investigator

Co-Investigators